Precigen Inc. Stock
Your prediction
Precigen Inc. Stock
Precigen Inc. dominated the market today, gaining €0.36 (7.590%).
Pros and Cons of Precigen Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Precigen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Precigen Inc. | 7.590% | 5.809% | 3.659% | 283.171% | 37.392% | 321.488% | 11.208% |
| Mighty River Power Ltd | 0.000% | 0.000% | 5.096% | 10.000% | 5.769% | -8.333% | -13.613% |
| CEMIG ADR | 1.640% | -1.587% | 2.198% | 16.250% | 8.772% | -19.828% | 27.267% |
| A2A SpA | 0.130% | -3.237% | 0.487% | 6.069% | -1.088% | 30.913% | 25.214% |
News
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
On July 1, 2026, Precigen (NASDAQ:PGEN) Chief Financial Officer Harry Thomasian Jr. reported the sale of 200,000 shares of common stock in multiple open-market transactions between June 29 and July
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing.
Transaction value
Precigen Q1 Earnings Call Highlights
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025
